Clinical Trial Update: Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma [Phase 4]

View source ↗

Summary

A Phase 4 trial assessing omalizumab for reducing inhaled corticosteroid use in severe IgE-mediated asthma was terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ige-mediated Asthma

Drugs mentioned

• Omalizumab (Omalizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Severe IgE-mediated Asthma | Phase 4 | Status: TERMINATED | Results posted: 2019-07-02